JP2020509010A5 - - Google Patents

Download PDF

Info

Publication number
JP2020509010A5
JP2020509010A5 JP2019546364A JP2019546364A JP2020509010A5 JP 2020509010 A5 JP2020509010 A5 JP 2020509010A5 JP 2019546364 A JP2019546364 A JP 2019546364A JP 2019546364 A JP2019546364 A JP 2019546364A JP 2020509010 A5 JP2020509010 A5 JP 2020509010A5
Authority
JP
Japan
Prior art keywords
antibody
fusion protein
cysteine
drug
occupied
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019546364A
Other languages
English (en)
Japanese (ja)
Other versions
JP7337698B2 (ja
JP2020509010A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020206 external-priority patent/WO2018160683A1/en
Publication of JP2020509010A publication Critical patent/JP2020509010A/ja
Publication of JP2020509010A5 publication Critical patent/JP2020509010A5/ja
Priority to JP2023135767A priority Critical patent/JP2023159335A/ja
Application granted granted Critical
Publication of JP7337698B2 publication Critical patent/JP7337698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019546364A 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体 Active JP7337698B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135767A JP2023159335A (ja) 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465129P 2017-02-28 2017-02-28
US62/465,129 2017-02-28
US201762561151P 2017-09-20 2017-09-20
US62/561,151 2017-09-20
PCT/US2018/020206 WO2018160683A1 (en) 2017-02-28 2018-02-28 Cysteine mutated antibodies for conjugation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135767A Division JP2023159335A (ja) 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体

Publications (3)

Publication Number Publication Date
JP2020509010A JP2020509010A (ja) 2020-03-26
JP2020509010A5 true JP2020509010A5 (https=) 2021-04-08
JP7337698B2 JP7337698B2 (ja) 2023-09-04

Family

ID=63370994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019546364A Active JP7337698B2 (ja) 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体
JP2023135767A Pending JP2023159335A (ja) 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135767A Pending JP2023159335A (ja) 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体

Country Status (13)

Country Link
US (1) US11938194B2 (https=)
EP (1) EP3589320A4 (https=)
JP (2) JP7337698B2 (https=)
KR (1) KR102697394B1 (https=)
CN (1) CN110352074B (https=)
AU (1) AU2018227807B2 (https=)
CA (1) CA3052837A1 (https=)
IL (1) IL268959B2 (https=)
MX (1) MX2019010028A (https=)
NZ (1) NZ756323A (https=)
SG (1) SG11201907288RA (https=)
TW (1) TW201840586A (https=)
WO (1) WO2018160683A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP2025530213A (ja) 2022-09-09 2025-09-11 ミリックス ファーマ リミテッド Nmt阻害剤を含む抗体薬物コンジュゲート及びその使用
CN115850449A (zh) * 2022-09-29 2023-03-28 苏州智核生物医药科技有限公司 抗体和缀合物
AU2024339683A1 (en) 2023-09-13 2026-03-26 Toray Industries, Inc. Pharmaceutical composition for treating, preventing and/or diagnosing cancer

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2011870A4 (en) 2006-04-14 2010-09-15 Medical & Biol Lab Co Ltd MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
FR2912465B1 (fr) 2007-02-12 2013-08-02 Jean Melchior Moteur a combustion interne alimente par un melange gazeux homogene pauvre.
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
JP5427348B2 (ja) 2007-10-12 2014-02-26 株式会社医学生物学研究所 エフェクター機能が向上した抗体
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
WO2012020065A1 (en) 2010-08-10 2012-02-16 Glycotope Gmbh Fab-glycosylated antibodies
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
EP3680251A1 (en) 2011-09-30 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules for promoting elimination of antigens
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2940451A1 (en) 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
LT3129406T (lt) 2014-04-11 2019-04-10 Medimmune, Llc Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
MX2016012830A (es) * 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
SG10201811124YA (en) * 2014-06-20 2019-01-30 Abgenomics Int Inc Her2 antibody-drug conjugates
SI3900742T1 (sl) 2014-09-11 2024-10-30 Seagen Inc. Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック, インコーポレイテッド 抗b7−h4抗体及び免疫複合体
MX2017003123A (es) * 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
US20160074527A1 (en) * 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
TWI812873B (zh) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
KR102574659B1 (ko) 2016-10-11 2023-09-04 비온디스 비.브이. 비선형 자가 희생 링커 및 이의 접합체
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor

Similar Documents

Publication Publication Date Title
JP2020509010A5 (https=)
CN111133002B (zh) 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
ES2667258T3 (es) Anticuerpos multivalentes
JP2022536898A (ja) 新規il-15プロドラッグおよびその使用方法
ES2618832T3 (es) Composición TNFR-FC estabilizada que comprende arginina
TWI680765B (zh) 自行穩定之接合劑共軛物
IL266202B2 (en) Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors
JP6426107B2 (ja) Apj受容体アゴニストおよびその使用
AU2014337367B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
CN102946858B (zh) 含有免疫球蛋白Fc的多肽的液体制剂
JP2021528431A (ja) Il−17に結合するためのペプチドリガンド
JP6949832B2 (ja) タンパク質コンジュゲート
TWI894130B (zh) 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
KR20140066124A (ko) 점도가 감소된 제제
KR20150132332A (ko) 저농도 항체 제형
US12383631B2 (en) Immune antigen specific IL-18 immunocytokines and uses thereof
JP2023159335A5 (https=)
WO2021080008A1 (ja) 1価ccap生成物の製造方法
EP4366778A1 (en) Antibody conjugates and manufacture thereof
JP2020532523A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
KR20230027267A (ko) 항-pd-1 항체 및 융합 단백질
CN116997337A (zh) 半乳糖缺陷型免疫球蛋白的双官能降解剂
US20240417436A1 (en) Conditionally activated immunocytokines and methods of use
TW201444576A (zh) 具有降低黏度的調配物
KR20240049858A (ko) 항체-약물 접합체 및 이의 사용방법